# US 7,608,686 B2 · Human tumor necrosis factor receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,686 B2
- Document ID: US7608686B2
- Status: Granted
- Kind: B2
- Application number: 11/767,350
- Filed: 2007-06-22
- Published: 2007-11-15
- Granted: 2009-10-27
- Earliest claimed: 2000-11-07
- Assignees: ZymoGenetics, Inc.
- Inventors: Jane A. Gross; Wenfeng Xu; Randal M. Henne; Francis J. Grant
- Web page: https://patentgrep.com/patent/US7608686B2

## CPC

- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.”

## Claims

### Claim 1

An isolated polypeptide selected from the group consisting of (a) a polypeptide consisting of amino acid residues 1 to 69 of the amino acid sequence of SEQ ID NO:2, and (b) a polypeptide consisting of amino acid residues 7 to 69 of the amino acid sequence of SEQ ID NO:2 wherein said polypeptide binds ZTNF4 that has the amino acid sequence of SEQ ID NO: 5.

### Claim 2 (depends on 1)

A fusion protein consisting of the polypeptide of claim 1 and an immunoglobulin moiety.

### Claim 3 (depends on 2)

The fusion protein of claim 2, wherein the fusion protein consists of a polypeptide consisting of amino acid residues 1 to 69 of SEQ ID NO:2.

### Claim 4 (depends on 2)

The fusion protein of claim 2, wherein the fusion protein consists of a polypeptide consisting of amino acid residues 7 to 69 of SEQ ID NO:2.

### Claim 5 (depends on 2)

The fusion protein of claim 2 wherein said immunoglobulin moiety is a Fc fragment.

### Claim 6 (depends on 5)

The fusion protein of claim 5 wherein said Fc fragment is Fc5.